Arabella Young

Arabella Young, PhD

Languages spoken: English

Academic Information

Departments Primary - Pathology

Academic Office Information

arabella.young@hci.utah.edu

Lab

Education History

Undergraduate University of Tasmania
 BBiotech(Hons)
Doctoral Training The University of Queensland
 PhD
Fellowship University of California San Francisco
 Postdoctoral Research Fellow

Selected Publications

Journal Article

  1. Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ (2018). A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Res, 78(4), 1003-1016. (Read full article)
  2. Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel (2017). MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer research, 77(17), 4697-4709. (Read full article)
  3. Ngiow SF*, Young A*, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth M (2016). Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer research, 76(21), 6266-6277. (Read full article)
  4. Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth M (2015). A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer research, 75(18), 3800-11. (Read full article)
  5. Young A*, Ngiow SF*, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth M (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer research, 77(17), 4684-4696. (Read full article)
  6. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold K (2018). Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes, 67(8), 1471-1480. (Read full article)
  7. Qadi AA, Taberlay PC, Phillips JL, Young A, West AC, Brettingham-Moore KH, Dickinson JL, Holloway A (2016). The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1. Journal of cellular biochemistry, 117(1), 49-58. (Read full article)
  8. Casciello F, Al-Ejeh F, Kelly G, Brennan DJ, Ngiow SF, Young A, Stoll T, Windloch K, Hill MM, Smyth MJ, Gannon F, Lee J (2017). G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 114(27), 7077-7082. (Read full article)
  9. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth M (2015). NK cells require IL-28R for optimal in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 112(18), E2376-84. (Read full article)
  10. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth M (2017). Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nature immunology, 18(9), 1004-1015. (Read full article)
  11. Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore K (2014). RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC cancer, 14, 808. (Read full article)
  12. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth M (2016). Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. Cancer cell, 30(3), 391-403. (Read full article)
  13. Poke FS, Upcher WR, Sprod OR, Young A, Brettingham-Moore KH, Holloway A (2012). Depletion of c-Rel from cytokine gene promoters is required for chromatin reassembly and termination of gene responses to T cell activation. PloS one, 7(7), e41734. (Read full article)
  14. Sutton LP, Jeffreys SA, Phillips JL, Taberlay PC, Holloway AF, Ambrose M, Joo JE, Young A, Berry R, Skala M, Brettingham-Moore K (2019). DNA methylation changes following DNA damage in prostate cancer cells. Epigenetics, 14(10), 989-1002. (Read full article)
  15. Young A, Mittal D, Stagg J, Smyth M (2014). Targeting cancer-derived adenosine: new therapeutic approaches. Cancer discovery, 4(8), 879-88. (Read full article)
  16. Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage (2018). Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell reports, 23(11), 3262-3274. (Read full article)
  17. Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone J (2020). Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science immunology, 5(52), (Read full article)
  18. VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry JA, Gebara E, Cross AR, Cheung LS, Dykema AG, Orcutt-Jahns BT, Henclová T, Golias J, Balolong J, Tomasovic LM, Funda D, Meyer AS, Pardoll DM, Hester J, Issa F, Hunter CA, Anderson MS, Bluestone JA, Raimondi G, Spangler J (2022). Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell reports, 41(3), 111478. (Read full article)
  19. Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold K (2022). Immune cells and their inflammatory mediators modify ß cells and cause checkpoint inhibitor-induced diabetes. JCI insight, 7(17), (Read full article)
  20. Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt (2023). Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. The oncologist, 28(10), e950-e959. (Read full article)
  21. Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani (2023). Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis. Journal of the Endocrine Society, 7(4), bvad012. (Read full article)
  22. Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan A (2024). Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. The oncologist, 29(5), 415-421. (Read full article)
  23. Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A*, Daud AI (2024). Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC reports, 2(1), 46. (Read full article)
  24. Quandt Z, Lucas A, Liang SI, Yang E, Stone S, Fadlullah MZH, Bayless NL, Marr SS, Thompson MA, Padron LJ, Bucktrout S, Butterfield LH, Tan AC, Herold KC, Bluestone JA, Anderson MS, Spencer CN, Young A, Connolly J (2025). Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. Journal for immunotherapy of cancer, 13(5), (Read full article)
  25. Li J, Al Faruque H, Cortes-Sanchez E, VanBrocklin M, Hu-Lieskovan S, Cina M, Young A, Kope'ek J, Yang (2025). Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma. Journal of controlled release, 387, 114193. (Read full article)
  26. Quandt Z, Young A, Barlow GL, Smith JA, Kusmartseva I, Dong S, Shapiro MR, Kang JH, Felton JL, Nguyen VQ, Szot G, Hassoun AA, Perdigoto AL, Herold KC, Nolan G, Bollyky PL, Brusko TM, Nakayama M, Cooper S, Anderson M (2025). Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Journal for immunotherapy of cancer, 13(8), (Read full article)
  27. Barlow GL, Schürch CM, Bhate SS, Phillips DJ, Young A, Dong S, Martinez HA, Kaber G, Nagy N, Ramachandran S, Meng J, Korpos E, Bluestone JA, Nolan GP, Bollyky P (2025). The extra-islet pancreas supports autoimmunity in human type 1 diabetes. eLife, 13, (Read full article)

Review

  1. Quandt Z*, Young A*, Perdigoto AL*, Herold KC, Anderson MS (2021). Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. [Review]. Annu Rev Med, 72, 313-330. (Read full article)
  2. Quandt Z, Young A, Anderson (2020). Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clinical and experimental immunology, 200(2), 131-140. (Read full article)
  3. Kang JH, Bluestone JA, Young (2021). Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends in immunology, 42(4), 293-311. (Read full article)
  4. Vijayan D, Young A, Teng MWL, Smyth M (2017). Targeting immunosuppressive adenosine in cancer. Nature reviews. Cancer, 17(12), 709-724. (Read full article)
  5. Ngiow SF, Young (2020). Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies. Frontiers in immunology, 11, 1633. (Read full article)
  6. Young A, Quandt Z, Bluestone J (2018). The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer immunology research, 6(12), 1445-1452. (Read full article)
  7. Cina ML, Venegas J, Young (2023). Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events. Immunological reviews, 318(1), 110-137. (Read full article)

Case Report

  1. Quandt Z, Coupe C, Anderson M, Uihlein A, Young (2020). Breaking ß Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. Journal of the Endocrine Society, 4(10), bvaa114. (Read full article)

Editorial

  1. Souza-Fonseca-Guimaraes F, Young A, Smyth M (2015). IFN type III: in vivo NK cell response. Oncotarget, 6(24), 19960-1. (Read full article)
  2. Young A, Bluestone J (2021). At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity. Cancer discovery, 11(3), 537-539. (Read full article)
  3. Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth M (2014). Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis. Oncoimmunology, 3(10), e958952. (Read full article)